key: cord-0049317-b2tm4t2l
authors: Zeng, Fanchu; Qin, Huan; Liu, Liming; Chang, Haocai; Chen, Qun; Wu, Linghua; Zhang, Le; Wu, Zhujun; Xing, Da
title: Photoacoustic-immune therapy with a multi-purpose black phosphorus-based nanoparticle
date: 2020-08-29
journal: Nano Res
DOI: 10.1007/s12274-020-3028-x
sha: e8e296cb1169f8b4c9d4c42da57118a60a53a414
doc_id: 49317
cord_uid: b2tm4t2l

Effective therapeutic strategies to precisely eradicate primary tumors with minimal side effects on normal tissue, inhibit metastases, and prevent tumor relapses, are the ultimate goals in the battle against cancer. We report a novel therapeutic strategy that combines adjuvant black phosphorus nanoparticle-based photoacoustic (PA) therapy with checkpoint-blockade immunotherapy. With the mitochondria targeting nanoparticle, PA therapy can achieve localized mechanical damage of mitochondria via PA cavitation and thus achieve precise eradication of the primary tumor. More importantly, PA therapy can generate tumor-associated antigens via the presence of the R848-containing nanoparticles as an adjuvant to promote strong antitumor immune responses. When combined with the checkpoint-blockade using anti-cytotoxic T-lymphocyte antigen-4, the generated immunological responses will further promote the infiltrating CD8 and CD4 T-cells to increase the CD8/Foxp3 T-cell ratio to inhibit the growth of distant tumors beyond the direct impact range of the PA therapy. Furthermore, the number of memory T cells detected in the spleen is increased, and these cells inhibit tumor recurrence. This proposed strategy offers precise eradication of the primary tumor and can induce long-term tumor-specific immunity. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available for this article at 10.1007/s12274-020-3028-x and is accessible for authorized users.

Developing effective therapeutic strategies to precisely eradicate primary tumors, inhibit metastases, and prevent tumor relapses, without side effects are the ultimate objectives in the battle against cancer. The current gold-standard cancer treatment approaches are surgery, chemotherapy, and radiotherapy, but none can completely achieve this goal [1] . Cancer immunotherapy is a very popular approach that stimulates the innate and adaptive immune systems against tumors and has been progressing rapidly, showing tremendous promise as a next generation tool for cancer treatment strategy [1, 2] . An important immune resistance mechanism involves immune inhibition (immune checkpoints) that normally mediates immune tolerance and tumor escape [2] [3] [4] [5] [6] . Checkpoint blockades are a corresponding monotherapy that will only succeed in the setting of a preexisting antitumor immune response [1, 4] . Therefore, to expand the efficacy of immunotherapy, a checkpoint blockade [4, 5, 7, 8] was combined with other traditional clinical therapies to induce de novo antitumor immune responses [9] .

Chemotherapy and radiation therapy can be combined with immunotherapy, for immune stimulation. This leads to tumorderived immunogenic cell death (ICD) and phagocytosis via released tumor antigens, promoting an antitumor immune response [10] [11] [12] [13] [14] [15] [16] [17] . This can be further combined with anticytotoxic T-lymphocyte antigen-4 (CTLA4) checkpoint blockades to suppress regulatory T-cells (Tregs) for a greater therapeutic effect. Chemotherapy or radiation therapy can be combined with immunotherapy, for significant antitumor efficacy and even a long-term tumor-specific immunity [18] [19] [20] [21] . However, the severe side effects of chemotherapy and radiation therapy still have not been overcome.

Synergistic photo-immunotherapy combination with CTLA4 checkpoint blockade is a promising treatment for cancer because it is non-invasive, with low systemic toxicity, good laser controllability, and excellent photoirradiation-dependent tumor selectivity [22] [23] [24] [25] [26] . However, the photodynamic therapy (PDT) effect was confined via low singlet oxygen (1O 2 ) to yield efficiency in the tumor site due to hypoxia in the tumor and aggregation-caused quenching (ACQ) of traditional photosensitizers (PSs) [27] [28] [29] [30] [31] [32] [33] . Another common phototherapy strategy (photothermal therapy (PTT)) includes a light-absorbing agent that accumulates in a tumor with near-infrared light. PTT converts light energy into heat and thermally ablates tumor cells. This indicates the ability to generate antitumor immunological effects by producing tumor-specific antigens from ablated tumor cell residues [6, [34] [35] [36] [37] . However, PTT may overheat in the general targeting area, thus causing unnecessary damage to normal tissues.

Photoacoustic therapy has recently emerged by targeting nanoparticles to tumor cells using photoacoustic (PA) shockwave to specifically destroy tumor cells [38] [39] [40] . The PA shockwave is created by the cavitation (growth and collapse) of nano-and micro-bubbles around nanoparticles heated by laser pulses. This produces a strong and localized mechanical disruption of the nearby tissue [38, [41] [42] [43] . The impact range of the PA shockwave is well defined due to the rapid decay of the sound wave intensity from the target tissue (approximately tens of micrometers) [44] . Versus other available therapies, PA therapy provides a distinct potential advantage: It can precisely eradicate primary tumors with minimal side effects on normal tissue. Despite these encouraging results, whether and how PA therapy can trigger any immunological response and exert any effect in inhibiting tumor metastasis remain largely unknown.

Recently, black phosphorus (BP) has emerged as an inorganic two dimensional nanomaterial with many novel properties, such as a large near-infrared extinction coefficient, a high photothermal conversion efficient, and an ultra-high surface to volume ratio that may allow for high drug-loading ability, as well as excellent biocompatibility and biodegradation, i.e., the final degradation products are nontoxic phosphate and phosphonate [45, 46] . Thus, BP nanoparticles are an important bio-material being used for bioimaging, phototherapy, and drug delivery [47, 48] .

Herein, we report a therapeutic strategy that combines adjuvant BP nanosheets-based PA therapy with a checkpointblockade immunotherapy. Biodegradable BP nanosheets with large near-infrared extinction coefficients were chosen as a PA therapy agent for converting laser energy to a PA shockwave. BP nanosheets were modified with tumor-targeting cyclic Arg-Gly-Asp (RGD) peptide, mitochondrion-targeting triphenylphosphine (TPP), and Resiquimod (R848) an immune-adjuvant with a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist, for producing an adjuvant effect. The nanoparticle termed here is BP/TPP/ RGD/R848. The mitochondria are mechanically destroyed by PA shockwaves when the BP/TPP/RGD/R848 specifically target mitochondria, with pulsed laser irradiation. This leads to cell apoptosis and thus precise PA therapy for eradication of a primary tumor with minimal side effects. More importantly, the PA therapy can generate tumor-associated antigens in the presence of the R848-containing nanoparticles as the adjuvant. This adjuvant can in turn promote strong antitumor immune responses. In combination with the checkpoint-blockade using CTLA4, the generated immunological responses will be further promoted to inhibit the growth of distant tumors beyond the direct impact range of PA therapy. This leads to a long-term immune effect to confine tumor cell regrowth. Figure 1 illustrates our overall treatment strategy with BP/TPP/RGD/R848.

BP was purchased from XFNANO Materials Tech Co., Ltd (Nanjing). N-methyl pyrrolidone (NMP) (99.5%, anhydrous), N-hydroxysuccinimide (NHS); 1-hydroxypyrrolidine-2,5-dione, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was purchased from Aladdin Reagents. The C[RGDyK] was purchased from TOP (Shanghai, China). Resiquimod (R848) was procured from InvivoGen (CA, USA). The (3carboxypropyl) triphenylphosphonium bromide (TPP) and NMP were obtained from J&K Chemical CO.

The BP was prepared by a simple liquid phase stripping technique. Briefly, BP (30 mg) powder was added to NMP (30 mL) in a 100 mL sealed conical tube and sonicated with a sonic tip for 4 h at 1,200 W. The ultrasonic frequency was from 19 to 25 kHz and the ultrasound probe worked every 2 s with an interval of 4 s. The dispersion was then sonicated in an ultrasonic bath continuously for another 1 h at 300 W. The temperature of the sample solution was kept below 277 K by an ice bath. The resulting dispersion was centrifuged for 20 min at 7,000 rpm, and the supernatant containing BP nanosheets was gently decanted. The BP nanosheet solution was centrifuged for 20 min at 12,000 rpm, and then the precipitate was repeatedly rinsed with water and re-suspended in an aqueous solution.

To produce the immuno-adjuvant R848 coating, BP (0.4 mg), was mixed in tri-distilled water (0.2 mL) and sonicated for 30 min to obtain BP dispersion (2 mg·mL -1 ). The R848 (0.5 mg·mL -1 , 0.2 mL) and bovine serum albumin (BSA) (0.5 mg·mL -1 , 0.2 mL) were added to the BP dispersion, and the mixture was uniformly mixed, sonicated in a water bath for 1 h, and stirred at room temperature for 6 h. An immunoadjuvant-modified BP (BP/R848) was obtained.

The EDC (9 mg) and NHS (6 mg) were added and stirred for 4 h. The solution was then treated with HS-PEG 2k -NH2 (20 mg·mL -1 , 0.5 mL). The reaction was carried out for 12 h at room temperature to a final concentration of HS-PEG 2k -NH2/ TPP (0.2 mmol). Next, BP/R848 (1 mg·mL -1 ) and HS-PEG 2k -NH2/TPP (0.2 mmol) were mixed and stirred at room temperature for 12 h, and distilled water was used to wash three times. The final BP/R848/ HS-PEG 2k -NH2/TPP (1 mg·mL -1 ) complex was obtained by centrifugation at 7,000 rpm for 10 min.

TPP (8 mg) was dissolved in DMSO (0.2 mL). Then, EDC (9 mg) and NHS (6 mg) were added and stirred for 4 h. The solution was treated with HS-PEG 2k -NH2 (20 mg·mL -1 , 2 mL) and C[RGDyK] peptide (10 μg). The reaction was carried out for 12 h at room temperature to reach a final concentration of HS-PEG 2k -NH2/TPP/RGD (0.2 mmol). Then BP/R848 (1 mg·mL -1 ) and HS-PEG 2k -NH2/TPP/RGD (0.2 mmol) were mixed and stirred at room temperature for 12 h, and distilled water was washed three times. The final HS-PEG 2k -NH2/TPP/RGD complex (1 mg·mL -1 ) was obtained by centrifugation at 7,000 rpm for 10 min.

Transmission electron microscopy (TEM) images were collected on a field emission high-resolution 2100F transmission electron microscope (JEOL, Japan) operating at an acceleration voltage of 200 kV. The atomic force microscopy (AFM) was performed on drop-cast flakes on Si/SiO2 substrates using the Series 5500 atomic force microscopy (Agilent, USA) under AC mode (tapping mode) in air. The size distribution of the nanoparticles was measured via a Malvern Zetasizer Nano ZS90 (Malvern, UK) instrument. The samples were recorded from 4,000 to 500 using a Nicolet Model 759 Fourier transform infrared spectrometer (FT-IR), and the samples were compressed with KBr crystals to detect infrared spectra. The optical characteristics of Cy5.5, BP, R848, TPP and BP/R848/TPP/Cy5.5 were investigated by UV-vis absorption (Lambda-35 UV-vis spectrophotometer, PerkinElmer, MA, USA).

4T1 cells and U87-MG cells were incubated in Dulbecco's modification of Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin-streptomycin, 10,000 U·mL -1 ) in a 37 °C humidified atmosphere containing 5% CO2. The DC2.4 cells, 4T1 cells, and MCF-7 cells were incubated in RPMI-1640 medium with 10% FBS and 1% antibiotics (penicillin-streptomycin, 10,000 U·mL -1 ) at 37 °C in a humidified atmosphere containing 5% CO2. Murine breast cancer 4T1 cells were cultured ender standard medium and conditions. A cell counting assay (CCK-8, Dojindo Laboratories, Kumamoto, Japan) was used to measure the cell viabilities.

BP/TPP/RGD/R848 was labeled with Cy5.5-NHS. The 4T1 cells were cultured with BP/TPP/RGD/R848/Cy5.5 and staining with MitoTracker to visualize mitochondria, under a confocal fluorescence microscope. Mitochondria were stained by MitoTracker (Beyotime Biotechnology, Catalog number: C1048) strictly following the standard protocol.

Mitochondrial regulation of apoptosis by JC-1 assay: The 4T1 cells were cultured with Laser, BP/TPP/RGD/R848 or BP/TPP/RGD/R848+Laser in a cell culture dish. After 12 h incubation at 37 °C, the mitochondria were stained with JC-1 (10 mg·mL -1 ) in DMEM for another 30 min. After washing with phosphate buffer saline (PBS) for 3 times, the cells were observed under a laser scanning confocal microscopy.

4T1 cells were cultured with Laser, BP/TPP/RGD/R848 or BP/TPP/RGD/R848+Laser in 35 mm glass-bottomed dishes. After 12 h of incubation at 37 °C, tumor cells were irradiated for 1 min by the pulsed laser (808 nm, at a fluence of 20 mJ·cm -2 , 20 Hz repetition rate, and 4 ns pulse duration). These samples were co-stained with calcein-acetylmethoxylate (calcein AM) and propidium iodide (PI) for 30 min at 37 °C and washed twice with PBS. Images were acquired with a confocal laser scanning microscope (ZEISS LSM 510 META, Germany). Calcein-AM and PI were purchased from Sigma-Aldrich Corporation (MO, USA).

The 4T1 cells were cultured with Laser, BP/TPP/RGD/R848 or BP/TPP/RGD/R848+Laser in cell culture dish. After 12 h of incubation at 37 °C, tumor cells were irradiated for 1 min by the pulsed laser (808 nm, at a fluence of 20 mJ·cm -2 , 20 Hz repetition rate, 4 ns pulse duration). Samples containing 10,000 cells each were run on a FACS Canto II flow cytometer with excitation at 488 nm. Fluorescein isothiocyanate (FITC) and PI were obtained from Sigma-Aldrich Corporation (MO, USA). The fluorescence emission of FITC was measured at 515-545 nm and the PI complexes were 564-606 nm.

To evaluate the activation of DCs by tumor-associated antibodies produced by PA therapy, the 4T1 cells were first seeded onto the abluminal side of the transwell filter (0.4 μm pore size) at a density of 1.0 × 10 5 cells per filter (1.12 cm 2 surface area, Corning Incorporated Life Sciences, USA). These samples were then cultured with BP/TPP/RGD, BP/TPP/RGD+Laser, R848, BP/TPP/RGD/R848 or BP/TPP/RGD/R848+Laser. The 4T1 cells were irradiated for 1 min by the pulsed laser (808 nm, at a fluence of 20 mJ·cm -2 , 20 Hz repetition rate, 4 ns pulse duration). The DC2.4 cells were cultured in the lower chamber of the transwell system. Both cells were incubated under normal culture conditions for 12 h. The DCs was collected and stained with anti CD80-PE and anti CD86-APC, and then sorted by flow cytometry.

Female Balb/c mice (10-20 g, 5-6 weeks) were obtained from Southern Medical University (Guangzhou, China). The animal study protocol was approved by the Institutional Animal Care and Use Committee at Southern Medical University (Guangzhou, China). To study the immune cells in secondary tumors, tumors were harvested from mice in different groups and homogenized into single cell suspension following the wellestablished protocol. Those antibodies were anti-CD8a-APC (Biolegend, Clone: 53-6.7, Catalog: 100712), anti-CD4-PerCP (Biolegend, Clone: GK1.5, Catalog: 100434) and used according to the manufacturer's protocols.

Cytotoxic T lymphocytes (CTLs) and helper T-cells were stained with CD4 -CD8 + and CD4 + CD8 -. To analyze CD4 

were CD3 + CD8 + CD62L + CD44 + and CD3 + CD8 + CD62L -CD44 + , respectively.

Serum samples and cell culture supernatants were isolated from mice after various treatments and diluted for analysis. TNF-α (BioLegend), IL-12 (BioLegend), and IFN-γ (BioLegend) were analyzed with ELISA kits according to vendor's instructions.

We first characterized the BP/TPP/RGD/R848 nanoparticles.

TEM revealed that the BP/TPP/RGD/R848 nanoparticle exhibited uniform spherical morphology with diameters of ~ 55 nm (Fig. 2(a) ). The AFM result was in accordance with the TEM analyses ( Fig. 2(b) ). BP nanosheets exhibited a uniform morphology with diameters of ~ 5 nm (Figs. S1 and S2 in the Electronic Supplementary Material (ESM)), which is consistent with previous studies [45, 46, 49] . The hydrodynamic diameter of BP/TPP/RGD/R848 was determined to be ~ 65 nm (Fig. 2(c) ), which is 57 nm larger than BP nanosheets (~ 6 nm) (Fig. S3 in the ESM). The presence of TPP, RGD, and R848 on the BP nanosheets surface was confirmed by Fig. 2(d) . The absorption bands at 3,350 cm -1 were associated with -NH2 groups in R848; bands at 1,633 cm -1 were associated with the -C=Cgroups in RGD; and bands at 790 and 770 cm -1 were attributed to the three substituted benzene vibration, which was observed in TPP, RGD and R848. These results confirmed that TPP, RGD, and R848 were modified on the BP nanosheets through the formation of amide bonds between the -COOH of TPP and the -NH2 of polyethylene glycol (PEG). The optical absorbance spectrum of BP/TPP/RGD/R848 exhibits typical features of TPP and R848 with peak absorbance at 262 and 365 nm (Fig. 2(e) ). Due to the good extinction coefficient of BP/TPP/RGD/R848 (Fig. S4 in the ESM), we observed a strong PA signal when the nanoparticles were irradiated with a single laser pulse (808 nm, 20 mJ·cm -2 ) with an ultrasonic transducer ( Fig. 2(f) ), indicating the generation of a mechanical wave.

Integrin αvβ3 is overexpressed by tumor cells and is a receptor for extracellular matrix proteins after exposure to RGD [21] . To investigate the cancer-targeting properties of BP/TPP/ RGD/R848 based on the decoration of RGD moieties, two tumor cells were studied for cellular uptake of Cy5.5-labelled BP/TPP/RGD/R848 by flow cytometry: MCF-7 cells with lower expressed αvβ3 integrin and 4T1 cells with overexpressed αvβ3 integrin. The fluorescence intensity of 4T1 cells was stronger 38% than that of MCF-7 cells (Figs. 3(a)-3(c)). These results indicated that the BP/TPP/RGD/R848 nanoparticle was specific to 4T1 breast tumor cells, these targeting are mainly mediated by the interaction between RGD and integrin. Next, the subcellular localization of BP/TPP/RGD/R848 was studied in cultured tumor cells. 4T1 cells stained with MitoTracker (to label mitochondria) were incubated with BP/TPP/RGD/R848. Confocal fluorescence images showed the co-localization of the two color channels, indicating that BP/TPP/RGD/R848 was in the mitochondria. Further, the Pearson correlation coefficients were higher than 0.956 (Fig. 3(d) ). Together, these results indicated that BP/TPP/RGD/R848 localized in the mitochondria.

Mitochondrion is a subcellular organelle that is the respiratory center of the cells [43] ; its damage can directly cause cellular apoptosis. The PA shockwave generated in PA cavitation could have destructive effects [50] . Whether the PA shockwave could damage mitochondria was investigated after BP/TPP/RGD/R848 localized in the mitochondria. JC-1 is a cationic dye used to evaluate mitochondrial function [51] . The green monomer of JC-1 can enter the cytoplasm and aggregate in normal mitochondria, forming a large number of red Jaggregates, the fluorescence transition from red to green indicates the mitochondrial dysfunction. The results demonstrate normal mitochondrial function (red fluorescence) in 4T1 cells treated with PBS, Laser, and BP/TPP/RGD/R848. Green fluorescence was observed for BP/TPP/RGD/R848+Laser, indicating mitochondrial dysfunction (Fig. 3(e) ). The results demonstrate that with an irradiated pulsed laser, the PA shockwave generated in mitochondria targeting nanoparticle-mediated PA cavitation could destroy cellular mitochondria.

We next used CCK-8 to measure the viability of 4T1 cells under different treatment conditions to investigate the in vitro therapeutic efficacy of mitochondria-targeting nanoparticlemediated PA therapy. Our results show that the effect of mitochondria targeting nanoparticle-mediated PA therapy depends on the concentration of nanoparticles at the same pulsed laser energy (808 nm, 20 mJ·cm -2 ). The cell viability decreases significantly as the concentration of nanoparticles increases. The activity was reduced to 32.4% when the concentration of the nanoparticles was 50 μg·mL -1 (Fig. S5 in the ESM). Therefore, we selected this optimal nanoparticle dose of 50 μg·mL -1 as well as a pulsed laser fluence of 20 mJ·cm -2 for PA therapy in all the following experiments.

To visually display the therapeutic efficiency of BP/TPP/ RGD/R848, cells were pretreated with the presence or absence of pulsed laser irradiation and then stained with Calcein-AM and PI to identify live and dead cells, respectively. Versus other groups, more red fluorescent cells were found for the BP/TPP/RGD/R848+Laser group; this was more lethal to tumor cells upon pulsed laser irradiation (Fig. 4(a) ).

Furthermore, the ratio of cell apoptosis and necrosis after different treatments was analyzed by flow cytometry with Annexin V-FITC/PI double staining ( Fig. 4(b) ). As expected, Control, Laser and BP/TPP/RGD/R848 treatment alone induced remarkable cell survival. In contrast, BP/TPP/RGD/R848+Laser treatment induced obvious cell apoptosis. Statistical analysis showed that the percentage of cells undergoing apoptosis significantly increased from 2.36% (Control) to 71.98% for the group of BP/TPP/RGD/R848+Laser, which confirmed PA cavitation to tumor cells. These results indicated that cell apoptosis was a major cell death modality for BP/TPP/RGD/ R848-based PA therapy.

To determine the physical range of damage generated by the PA shockwave, we assessed the cell viability of a mixed cell culture preparation. We detected the co-plated 4T1 cells and MCF-7 cell morphology before and after PA therapy with an optical microscope. The 4T1 cells with BP/TPP/RGD/R848+ Laser were destroyed (Fig. 4(c) , first column, marked with arrows), and the adjacent MCF-7 cell morphology remained intact due to the specificity of the nanoparticles.

As a control, we plated 4T1 cells and MCF-7 cells alone with the nanoparticle. In these control groups, a shockwave could be generated within every cell depending on the efficacy of the PA therapy for the different cell types, and cell viability would be reflected accordingly. After subjecting all three groups to identical doses of PA treatment (50 μg·mL -1 , 20 mJ·cm -2 ), the cytotoxic efficacy of the therapy was tested with a CCK-8 cell viability assay. We found that the viability of the co-plated cells (63.7%) was statistically higher than that of the 4T1 cells alone (31.4%) and lower than the MCF-7 cells alone (82.3%) ( Fig. 4(d) ). These results suggest that PA therapy could be a precise method to kill tumor cells with minimal damage to the adjacent tissue with a proper dosimetry.

Dendritic cells (DCs) are the most potent antigen presenting cells (APCs). DCs efficiently capture antigens in peripheral tissues and process these antigens to form major histocompatibility complex (MHC-peptide) complexes [52] . These immature DCs acquire a unique ability to migrate from the periphery of the secondary lymphoid organ to the T cell region following antigen uptake [53] . As cells move, they mature and alter the distribution of cell surface molecules, attracting resting T-cells and presenting their antigenic load [54] . The upregulation of co-stimulatory molecules, CD80 and CD86, as the typical markers on the surface of DCs may indicate the level of DC maturation [22] . Whether and how PA therapy triggers an immunological response and inhibits tumor remains largely unknown. Thus, we selected a universally recognized immature DC cell line, DC 2.4 cells [36] , to investigate the immune activation characteristics after PA therapy.

A transwell system was then used to study such effects at the in vitro level [22] . In our experiment, the upper chamber containing 4T1 tumor cells after various treatments was placed into the transwell system. The lower chamber was seeded with DC2.4 ( Fig. 5(a) ). The DC maturation and cytokine secretion from DCs were then evaluated by flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively. Versus the DC maturation level after culturing DC2.4 without 4T1 cells (Fig. S6 in the ESM) , the addition of BP/TPP/RGD/ R848 nanoparticles into this system resulted in a slight increase of DC maturation (Figs. 5(b) and 5(c) ). In contrast, if those 4T1 cells were treated by PA therapy using BP/TPP/RGD+Laser or BP/TPP/RGD/R848+Laser, their residues could remarkably promote DC maturation, particularly if BP/TPP/RGD/R848+ Laser was used (Figs. 5(b) and 5(c) ).

Consistent with DC maturation data, we also found that 4T1 tumor cell residues post-PA therapy treatment with BP/TPP/ RGD/R848+Laser triggered the highest levels of interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) secretion by DC2.4 (Figs. 5(d)-5(f)). Our results suggest that tumor-associated antigens from tumor cell residues post-PA therapy could trigger effective DC maturation, especially with R848-loaded nanoparticles as the adjuvant.

The preferential accumulation of BP/TPP/RGD/R848 in tumor regions was investigated on a systemic level. The biodistribution of BP/TPP/RGD/R848/Cy5.5 was examined using an in vivo fluorescence imaging system at multiple time points post-injection. BP/TPP/RGD/R848/Cy5.5-treated mice have much higher fluorescence intensities in their tumors, indicating accumulation of BP/TPP/RGD/R848 in tumors (Figs. 6(a) and 6(b)). The fluorescence intensity reaches a maximum for BP/TPP/RGD/R848/Cy5.5 twelve hours post-injection. The PA images of solid tumors at various time points result was in accordance with the fluorescence intensities analyses (Fig. S7 in the ESM). Considering the biosafety of nanoparticles in vivo, we sacrificed the mice after 12, 24, 36, and 48 h of injection of nanoparticles and harvested their main organs. The main organs and tumor tissues were spectrally imaged by an ODYSSEY Infrared Imaging System (Fig. S8(a) in the ESM). The averaged fluorescent intensity of each imaged organ was calculated for a semiquantitative biodistribution analysis ( Fig. S8(b) in the ESM). A strong fluorescent signal was observed in tumors and reticuloendothelial systems including the liver, spleen and lung. In addition, the absorption of BP gradually decrease with extend incubation time (Fig. S9(a) in the ESM), and it was almost colorless and transparent by the eighth day ( Fig. S9(b) in the ESM). These results implied the biodegradability of BP. Finally, histological analysis of major organs was examined for potential side effects exhibiting undetectable pathological abnormalities and adverse reactions (Fig. S10 in the ESM), which suggested negligible systemic toxicity of the BP/TPP/ RGD/R848-based PA therapy.

We next determined whether PA therapy with our BP/TPP/ RGD/R848 could trigger immunological responses in vivo. BALB/c mice bearing 4T1 breast tumor were intravenously injected with BP/TPP/RGD or BP/TPP/RGD/R848 and then irradiated by 808 nm laser at 20 mJ·cm −2 for 20 min to ablate tumors via the PA effect from our previous studies [39] [40] [41] 55] . At 72 h after PA therapy, mice were killed, and their spleens were collected for flow cytometry after co-staining with various markers. The results suggested that CD80 and CD86 were significantly upregulated in vivo, and PA tumor ablation with adjuvant nanoparticles (BP/TPP/RGD/R848+Laser) induced a high level of DC maturation (Figs. 6(c) and 6(d)), which appeared to be much higher than that observed for adjuvant nanoparticles alone (BP/TPP/RGD/R848 without laser) or PA therapy with BP/TPP/RGD in the absence of immune-adjuvant. Therefore, after the tumor is destroyed via PA therapy, DCs may be recruited to the ablated tumor site as antigen-presenting cells to trigger immune responses.

Tumor-associated antigens in tumor debris post PA therapy can be transported into nearby lymph nodes and then processed by DCs to simulate DC maturation via the adjuvant nanoparticles. Cytokine secretion is also important in immune responses. In a parallel experiment, the sera of mice bearing 4T1 tumors after different treatments were collected at 72 h to analyze the changes of various cytokines including IL-12, TNF-α, and IFN-γ (Figs. 6(e)-6(g)). Similarly, although BP/TPP/RGD/R848 injection alone or PA therapy with BP/TPP/RGD could increase the secretion of pro-inflammatory cytokines, the secretions induced by BP/TPP/RGD/R848-based PA therapy were noticeably higher; this was favorable for triggering an anti-tumor immune response. These results suggest that BP/TPP/RGD/R848-based PA therapy could induce immunological stimulation effects in vivo.

Next, we assessed whether such robust immunological responses triggered by PA therapy with BP/TPP/RGD/R848 would be able to inhibit the growth of tumor cells left behind after PA therapy at distant sites. The blockade of CTLA4 has been approved by the US Food and Drug Administration (FDA) for cancer treatment and may suppress the immuno-suppressive regulatory capacity of Tregs [56] [57] [58] . Thus, in our animal experiments, CTLA-4 blocking therapy was introduced to enhance the anti-cancer immuno-therapy efficacy generated in situ after precise PA ablation of primary tumors based on BP/TPP/RGD/R848. Mice that bore bilateral 4T1 breast tumor flank tumors underwent CTLA4 treatment. The tumors in the left flanks (primary tumors) were designed for BP/TPP/RGD/R848based PA therapy, and the tumors in the right flanks were designed without direct treatment as an artificial model of abscopal tumor. On the 1 st day, nanoparticles (1 mg·mL -1 0.2 mL) were intravenously injected, and the left tumor received PA therapy. On the 2 nd , 4 th , and 6 th day, the mice were intravenously injected with anti-CTLA4 (1 mg·mL -1 15 μL) ( Fig. 7(a) ).

The tumor sizes on both sides that primary tumors with direct PA therapy treatment and distant tumors without PA therapy treatment were then measured (Figs. 7(b) and 7(c) ). The control, Laser, BP/TPP/RGD/R848, and anti-CTLA4 injection alone showed no appreciable inhibitory effect on both primary and distant tumor growth. The tumor growth was partly delayed in BP/TPP/RGD/R848+anti-CTLA4 due to the non-specific immune responses elicited by adjuvant nanoparticles and anti-CTLA4. PA therapy (BP/TPP/RGD/R848+Laser) could only ablate primary tumors, not effectively inhibit distant tumors. In contrast, combining PA therapy with anti-CTLA4 therapy not only significantly suppressed their growth within the first 12 days post-treatment, but also offered remarkably synergistic effects to eliminate abscopal tumors, whose sizes gradually shrunk after their primary tumors on the contralateral side were treated by PA therapy and then disappeared after about 10 days.

We also found that 80% of 4T1 tumor-bearing mice could survive for 58 days after BP/TPP/RGD/R848-based PA therapy and anti-CTLA4 therapy (Fig. 7(d) ); this is in marked contrast to mice in the other six control groups which all died within 36-48 days. The body weight of the mice in the seven treatment groups had no significant changes throughout the entire treatment, suggesting negligible systemic toxicity (Fig. 7(e) ). In addition, hematoxylin-eosin staining (H&E) analysis of tumor tissues revealed that the PA therapy group combined with CTLA4 blockade exhibited much more pyknotic cells with highly condensed nuclei (apoptotic/necrotic) (Fig. 7(f) ). Then, tumor-bearing mice irradiated with pulsed laser, also displaying non-obvious temperature increasing. Thus, minimal heating effect was observed upon pulsed laser irradiation in vivo, suggesting the non-thermal property of photoacoustic modality (Fig. S11 in the ESM). The highest in vivo antitumor therapeutic efficacy likely resulted from the integrated advantages of PA therapy combined with CTLA4 blockade, including strong PA cavitation that could mechanically disrupt intracellular organelles.

Immune cells in secondary 4T1 tumors were studied on day 7 to understand how the mechanism of synergistic anti-tumor effects triggered by BP/TPP/RGD/R848-based PA therapy in combination with anti-CTLA4 therapy interact with the immunological system ( Fig. 8(a) ). CTLs (CD3 + CD4 − CD8 + ) play a positive role in attacking tumor cells and could directly kill targeted tumor cells by releasing the cytotoxins-IFN-γ, perforin, granzymes, and granulysin [59, 60] . In our experiments, treatment with free anti-CTLA-4 or BP/TPP/RGD/R848 alone failed to promote CD8 + CTL infiltration into secondary tumors ( Fig. 8(b) ). In contrast, the percentage of total T cells in secondary tumors showed a significant increase after treatment with BP/TPP/ RGD/R848 in combination with anti-CTLA-4 ( Fig. S12 in the ESM). Of note, the percentage of CD8 + CTL in secondary tumors in mice after BP/TPP/ RGD/R848-based PA therapy combined with anti-CTLA-4 treatment dramatically increased to 25% (Figs. 8(b) and 8(e)) and was significantly enhanced with indirect immunohistochemistry on frozen sections of secondary tumors in mice (Fig. 8(c) ).

CD4 + helper T-cells (CD3 + CD4 + CD8 -) play important roles in the regulation of adaptive immunity; they can be classified into effector T-cells (Teff) and may stimulate and interact with other leukocytes by secreting cytokines as well as Tregs that suppress antitumor immunity [61] [62] [63] . On day 7, abscopal tumors were harvested for analysis by flow cytometry. A large amount of Tregs remained in the secondary tumors of mice after ablation of primary tumors based on BP/TPP/RGD/R848-based PA therapy. Thus, although a vaccine-like immune response is generated based on BP/TPP/RGD/R848-based PA therapy, the anti-tumor efficacy of this group is still less effective due to the presence of large amounts of Tregs.

CTLA-4 blockade treatment can significantly reduce Tregs cells (CD3 + CD4 + Foxp3 + ) in secondary tumors (Figs. 8(d) and 8(e) ).

Thus, the ratio of CD8 + CTL/Tregs and CD4 + Teff/Tregs cells was significantly enhanced in secondary tumors in post-treatment mice based on BP/TPP/RGD/R848-based PA therapy plus anti-CTLA-4 treatment (Fig. S13 in the ESM). In addition, versus the four other groups shown in Fig. 8 , BP/TPP/RGD/ R848-based PA therapy combined with anti-CTLA4 induced the highest percentage of CD8 + CTL (also CD8 + CTL/Tregs ratio) responsible for cancer immunotherapy. We also tested cytokines, including TNF-α and IFN-γ in serum samples, from all mice on day 7 by ELISA. The results showed that the circulating cytokines of IFN-γ and TNF-α in serum were increased after PA therapy combined with anti CTLA4 treatment (Figs. 8(f) and 8(g) ). The immune responses collectively suggest that tumor-associated antigens produced after PA 

An important feature of immunological memory is the ability of the immune system to protect organisms from previously encountered pathogens, including neoplastic diseases. Thus, it is necessary to assess immune memory induced by BP/TPP/ RGD/R848-based PA therapy combined with anti CTLA4. In our experiments, secondary 4T1 tumors were inoculated 40 days after BP/TPP/RGD/R848-based PA therapy to remove their first 4T1 tumor. Two rounds of treatment were given intravenously with anti-CTLA-4 antibody on different days (1 mg·mL -1 25 μL). The first round was given immediately after the first tumor was eliminated (1 st , 3 rd and 5 th day). The second round was injected on days 41, 44, and 47 after re-inoculation of its secondary tumor ( Fig. 9(a) ).

We next carried out a series of analyses to understand whether a robust tumor immune memory was generated and how the antitumor immune memory was induced after PA therapy, especially when combined with the CTLA4 blockade.

Memory T-cells are classified into central memory T-cells (TCM) and effector memory T-cells (TEM) based on effector function, proliferative capacity, and migration potential [64, 65] . After being stimulated by antigen, TCM cells can rapidly proliferate, differentiate, and migrate to infected tissues [66] . In contrast to TCM cells, TEM cells can induce a strong immune memory effect by producing vital cytokines such as TNF-α and IFN-γ upon a second encounter with the same antigen [58, [67] [68] [69] .

On day 50, we collected spleens from different groups of mice and measured changes in central memory CD8 + T-cells (TCM) The TNF-α and IFN-γ levels in sera from mice detected at 7 days after various treatments. Data are shown as mean ± SD (n = 4). P values: * P < 0.05, ** P < 0.01, *** P < 0.001, ANOVA. and effector memory CD8 + T-cells (TEM). Flow cytometry analysis showed that the percentage of TEM cells (CD3 + CD8 + CD44 + CD62L − ) after PA therapy plus anti-CTLA-4 antibody to remove the first tumors was much higher than that of the control group in which tumors were treated with PA therapy, intravenous injection of nanoparticles, or intravenous injection of nanoparticles combined with anti-CTLA-4 (Figs. 9(b) and 9(c)). In contrast, the percentage of TCM cells (CD3 + CD8 + CD44 + CD62L + ) in the combination therapy group was much lower than that of the three control groups (Fig. S14 in the ESM). Furthermore, concentrations of TNF-α, IFN-γ, and IL-12 in sera increased after PA therapy combined with CTLA-4 blockade 1 week after mice were challenged with secondary tumors (Figs. 9(d)-9(f)). Our data strongly suggest that PA therapy plus CTLA-4 blockade can boost immune memory to effectively prevent tumor recurrence.

In this study, we describe PA tumor ablation with immuneadjuvant nanoparticles together with checkpoint-blockade therapy. This approach precisely eradicates primary tumors with minimal side effects on normal tissue. It also inhibits metastases and prevents tumor relapses. PA can precisely ablate tumors with multifunctional nanoparticles encapsulating both biodegradable and biocompatible BP. Immune-adjuvant toll-like receptor agonists can induce vaccine-like immune responses that may be combined with CTLA4 checkpoint blockade to realize highly effective cancer immunotherapy. Great anti-tumor efficacy has been observed using this strategy to treat an abscopal tumor model that can promote infiltrating CD8 and CD4 T-cells. Furthermore, a strong immune-memory effect was observed 50 days after PA tumor ablation with the nanoparticles. These data, along with anti-CLTA4 therapy, protected mice from tumor re-challenge. We further demonstrate that such a treatment strategy may also be realized with systemic injection of all agents. Therefore, our study presents a new cancer treatment strategy, that can eliminate primary tumors, attack and kill spreading distant tumors, and offer immunememory protection to prevent tumor relapse. Considering that most of the components of our nanoparticles are FDAapproved and biodegradable, our technique may be optimal for future clinical translation.

Photothermal therapy with immune-adjuvant nanoparticles together with

R848 PA therapy and CTLA4 blockade combination therapy to inhibit cancer relapse. (b) Proportions of effector memory T cells (TEM) in the spleen analyzed by flow cytometry (gated on CD8 + and CD3 + T cells). (c) Quantification of T cells (TEM) expression by flow cytometry after various treatments. (d)-(f) TNF-α, IFN-γ and IL-12 levels in sera from mice isolated seven days after mice were re-challenged with secondary tumors (on day 47) (four mice per group). Data are shown as mean ± SD (n = 4)

Thermal ablation of tumours: Biological mechanisms and advances in therapy

The blockade of immune checkpoints in cancer immunotherapy

Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer

Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer

Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy

Deep-level defect enhanced photothermal performance of bismuth sulfide-gold heterojunction nanorods for photothermal therapy of cancer guided by computed tomography imaging

Cancer immunotherapy using checkpoint blockade

Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy

Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy

Perfluorocarbon-loaded hollow Bi 2 Se 3 nanoparticles for timely supply of oxygen under near-infrared light to enhance the radiotherapy of cancer

Cancer nanomedicine for combination cancer immunotherapy

Combining radiotherapy and cancer immunotherapy: A paradigm shift

Self-supplied tumor oxygenation through separated liposomal delivery of H 2 O 2 and catalase for enhanced radioimmunotherapy of cancer

Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

Using immunotherapy to boost the abscopal effect

Programmable chemotherapy and immunotherapy against breast cancer guided by multiplexed fluorescence imaging in the second near-infrared window

Robust antitumor responses result from local chemotherapy and CTLA-4 blockade

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy

Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer

Nanozyme decorated metalorganic frameworks for enhanced photodynamic therapy

Activatable hybrid nanotheranostics for tetramodal imaging and synergistic photothermal/photodynamic therapy

Responsive assembly of upconversion nanoparticles for pH-activated and near-infrared-triggered photodynamic therapy of deep tumors

A size-reducible nanodrug with an aggregationenhanced photodynamic effect for deep chemo-photodynamic therapy

Organic semiconducting pro-nanostimulants for nearinfrared photoactivatable cancer immunotherapy

Innovative strategies for hypoxic-tumor photodynamic therapy

Systemic antitumor immunity by PD-1/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors

Nanoscale metal-organic framework overcomes hypoxia for photodynamic therapy primed cancer immunotherapy

Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy

Smart nanoreactors for pH-responsive tumor homing, mitochondria-targeting, and enhanced photodynamic-immunotherapy of cancer

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

Dual-peak absorbing semiconducting copolymer nanoparticles for first and second near-infrared window photothermal therapy: A comparative study

Metabolizable semiconducting polymer nanoparticles for second near-infrared photoacoustic imaging

Antigendirected fabrication of a multifunctional nanovaccine with ultrahigh antigen loading efficiency for tumor photothermal-immunotherapy

Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis

Photoacoustic therapy for precise eradication of glioblastoma with a tumor site blood-brain barrier permeability upregulating nanoparticle

The use of femto-second lasers to trigger powerful explosions of gold nanorods to destroy cancer cells

Fluorescence quenching nanoprobes dedicated to in vivo photoacoustic imaging and highefficient tumor therapy in deep-seated tissue

Imaging-guided photoacoustic drug release and synergistic chemo-photoacoustic therapy with paclitaxel-containing nanoparticles

Explosible nanocapsules excited by pulsed microwaves for efficient thermoacoustic-chemo combination therapy

Mitochondriatargeting photoacoustic therapy using single-walled carbon nanotubes

Proteinassisted fabrication of nano-reduced graphene oxide for combined in vivo photoacoustic imaging and photothermal therapy

Highspeed in vitro intensity diffraction tomography

Stable and multifunctional dye-modified black phosphorus nanosheets for nearinfrared imaging-guided photothermal therapy

Biodegradable black phosphorus-based nanospheres for in vivo photothermal cancer therapy

Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/ photothermal/chemotherapy of cancer

Fast-acting black-phosphorus-assisted depression therapy with low toxicity

Black phosphorus nanosheets as a robust delivery platform for cancer theranostics

A photoacoustic shockwave triggers the size shrinkage of nanoparticles to obviously improve tumor penetration and therapeutic efficacy

Pulsed microwave-pumped drug-free thermoacoustic therapy by highly biocompatible and safe metabolic polyarginine probes

Dendritic cells: Specialized and regulated antigen processing machines

Induction of interleukin 10-producing, nonproliferating CD4 + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

A paradigm shift in cancer immunotherapy: From enhancement to normalization

Chemo/ photoacoustic dual therapy with mRNA-triggered DOX release and photoinduced shockwave based on a DNA-gold nanoplatform

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies

Enhancement of antitumor immunity by CTLA-4 blockade

Dendritic cell-induced memory T cell activation in nonlymphoid tissues

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

Xenogeneic proliferation and lymphokine production are dependent on CD4 + helper T cells and self antigen-presenting cells in the mouse

Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4 + helper T cells. A model for the long-term survival of memory cells

Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

CCR7 expression and memory T cell diversity in humans

Similarities and differences in CD4 + and CD8 + effector and memory T cell generation

Effector and memory T-cell differentiation: Implications for vaccine development

Targeting and specific activation of antigen-presenting cells by endogenous antigen-loaded nanoparticles elicits tumor-specific immunity

The authors declare no conflict of interest.